In our previous study, we found that the AXL/AKT pathway promotes BRAF inhibitor resistance in melanoma with wild-type PTEN, but not in melanoma with impaired PTEN26, indicating that PTEN status affects the molecular route to resistance to BRAF inhibition in melanoma27. This evidence concerns the gene AXL and melanoma.